Immunogenicity and safety of prophylactic HPV vaccines in people living with HIV: A systematic review and meta-analysis.
Hum Vaccin ImmunotherSep 2, 2026 (epub)
Bahar Senel, Gokhan Senel, Ceren Elma
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the immunogenicity and safety of prophylactic HPV vaccines in people living with HIV (PLWH). The analysis included 12 studies with 1,493 participants for HPV16. The results showed high seroconversion rates: 97.8% for HPV16, 94.2% for HPV18, 97.0% for HPV6, and 97.1% for HPV11, indicating effective vaccination in this population.
Key findings
- HPV16 seroconversion was 97.8% in PLWH, with a 95% confidence interval of 94.9-99.1%.
- CD4 count significantly influenced immunogenic response, with 98.5% seroconversion in those with CD4 > 350 cells/µL.
- Two doses of the nonavalent vaccine were non-inferior to three doses in virologically suppressed women.
- No vaccine-related serious adverse events were reported.
Why it matters
The findings highlight the importance of HPV vaccination in PLWH, particularly before severe immunosuppression occurs, to reduce the risk of HPV-related malignancies. High seroconversion rates across vaccine generations support current vaccination guidelines.